Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia.

ABSTRACT:

Background

FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a variable proportion of wild-type FLT3 patients also responded to these drugs.

Methods

We analyzed 6 different transcriptomic datasets of AML cases. Differential expression between mutated and wild-type FLT3 AMLs was performed with the Wilcoxon-rank sum test. Hierarchical clustering was used to identify FLT3-mutation like AMLs. Finally, enrichment in recurrent mutations was performed with the Fisher's test.

Results

A FLT3 mutation-like gene expression pattern was identified among wild-type FLT3 AMLs. This patter

SUBMITTER: Mosquera Orgueira A 

PROVIDER: S-EPMC7886212 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature